Center for Advanced Studies in Nanotechnology for Chemical, Food and Agricultural Industries, KU Institute for Advanced Studies, Kasetsart University, Bangkok, 10900, Thailand.
Interdisciplinary Graduate Program in Bioscience, Faculty of Science, Kasetsart University, Bangkok, 10900, Thailand.
Appl Microbiol Biotechnol. 2019 Oct;103(20):8427-8438. doi: 10.1007/s00253-019-10116-6. Epub 2019 Sep 10.
Human epidermal growth factor receptors (EGFR) are an important target in drug discovery in terms of both protein-small-molecule interactions and protein-protein interactions. In this work, the isolation of a stable soluble protein of the tyrosine kinase domain of EGFR in Escherichia coli expression has been accomplished. This successful study presents the expression and purification conditions to obtain a stable soluble protein of the active tyrosine kinase domain of EGFR (EGFR-TK) and ErbB2 (ErbB2-TK) in a bacterial system, albeit in relatively low yields. The recombinant gene was inserted into a pColdI vector and recombinant protein was expressed at low temperature. Purification of EGFR-TK and ErbB2-TK took place under the same conditions by purified supernatant using a diethylaminoethyl sepharose column followed by anion exchange and size-exclusion chromatography columns. The final yields of purified EGFR-TK and ErbB2-TK were 8.4 and 9.5 mg per liter of culture, respectively. Determination of EGFR-TK and ErbB2-TK was performed via enzyme activity with commercial drugs. The IC values of erlotinib and afatinib against EGFR-TK were 13.09 nM and 2.36 nM respectively, while the IC values of lapatinib and afatinib against ErbB2-TK were 24.69 nM and 1.36 nM, respectively. These results confirmed that soluble proteins of the active intracellular domain of the HERs family were successfully expressed and purified in a bacterial system. The new protein expression and purification protocol will greatly facilitate the enzymatic inhibition and structural studies of this protein for drug discovery.
人类表皮生长因子受体(EGFR)是蛋白质-小分子相互作用和蛋白质-蛋白质相互作用方面药物发现的重要靶标。在这项工作中,成功地在大肠杆菌表达系统中分离出 EGFR 酪氨酸激酶结构域的稳定可溶性蛋白。这项成功的研究提出了表达和纯化条件,以在细菌系统中获得 EGFR(EGFR-TK)和 ErbB2(ErbB2-TK)的活性酪氨酸激酶结构域的稳定可溶性蛋白,尽管产量相对较低。重组基因被插入 pColdI 载体中,并在低温下表达重组蛋白。通过使用 DEAE 琼脂糖柱纯化上清液,在相同条件下对 EGFR-TK 和 ErbB2-TK 进行纯化,然后进行阴离子交换和分子筛层析柱。纯化的 EGFR-TK 和 ErbB2-TK 的最终产量分别为每升培养物 8.4 和 9.5 毫克。通过商业药物的酶活性测定来确定 EGFR-TK 和 ErbB2-TK。厄洛替尼和阿法替尼对 EGFR-TK 的 IC 值分别为 13.09 nM 和 2.36 nM,而拉帕替尼和阿法替尼对 ErbB2-TK 的 IC 值分别为 24.69 nM 和 1.36 nM。这些结果证实了 HERs 家族的活性细胞内结构域的可溶性蛋白在细菌系统中成功表达和纯化。新的蛋白质表达和纯化方案将极大地促进该蛋白的酶抑制和结构研究,以用于药物发现。